Displaying Tetra-Membrane Spanning Claudins on Enveloped Virus-Like Particles for Cancer Immunotherapy

2017 ◽  
Vol 13 (3) ◽  
pp. 1700345 ◽  
Author(s):  
Irene C. Schneider ◽  
Jessica Hartmann ◽  
Gundula Braun ◽  
Jörn Stitz ◽  
Thorsten Klamp ◽  
...  
1982 ◽  
Vol 145 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Y. E. Vaucher ◽  
C. G. Ray ◽  
L. L. Minnich ◽  
C. M. Payne ◽  
D. Beck ◽  
...  

1998 ◽  
Vol 4 (S2) ◽  
pp. 1054-1055
Author(s):  
A. J. Wasserman ◽  
H. Wang ◽  
G. Clark ◽  
J. R. Megill ◽  
S.K. Durham

Analysis of Hepatitis C virus (HCV) assembly and packaging, and the study of virus-cell interactions, have been impeded by the lack of a robust cell culture system and a viable small animal model. Recently, an alternative approach utilizing recombinant gene technology has been implemented. We describe a system in which specific HCV genes are cloned into a baculovirus to form a recombinant baculovirus expression vector that produces HCV proteins that self-assemble into enveloped virus-like particles (VLP). Four HCV structural genes were cloned into the baculovirus expression vector under the control of the polyhedrin promoter, and were then recombined with baculovirus DNA. A baculovirus with no HCV insert served as a negative control (wild-type). Ovary cells (Spodoptera frugiperda) were infected with either the recombinant or wild type baculovirus. Five-days post-infection, a group of cells were harvested, fixed in McDowell-Trumps solution, and routinely prepared for transmission electron microscopy (TEM).


Vaccine ◽  
2019 ◽  
Vol 37 (44) ◽  
pp. 6656-6664
Author(s):  
Young-Man Kwon ◽  
Youri Lee ◽  
Ki Hye Kim ◽  
Yu Jin Jung ◽  
Zhuo Li ◽  
...  

Vaccine ◽  
2019 ◽  
Vol 37 (47) ◽  
pp. 7070-7080 ◽  
Author(s):  
Patricia Pereira Aguilar ◽  
Tobias Amadeus Schneider ◽  
Viktoria Wetter ◽  
Daniel Maresch ◽  
Wai Li Ling ◽  
...  

Biomaterials ◽  
2021 ◽  
Vol 271 ◽  
pp. 120726
Author(s):  
Wenjing Li ◽  
Zhe Jing ◽  
Shuqing Wang ◽  
Qiyu Li ◽  
Yutong Xing ◽  
...  

Author(s):  
Lise Chauveau ◽  
Anne Bridgeman ◽  
Tiong Kit Tan ◽  
Ryan Beveridge ◽  
Joe Frost ◽  
...  

AbstractCyclic GMP-AMP (cGAMP) is an immunostimulatory second messenger produced by cGAS that activates STING. Soluble cGAMP acts as an adjuvant when administered with antigens. cGAMP is also incorporated into enveloped virus particles during budding. We hypothesised that inclusion of the adjuvant cGAMP within viral vaccine vectors would promote adaptive immunity against vector antigens. We immunised mice with virus-like particles (VLPs) containing the HIV-1 Gag protein and VSV-G. Inclusion of cGAMP within these VLPs augmented splenic VLP-specific CD4 and CD8 T cell responses. It also increased VLP- and VSV-G-specific serum antibody titres and enhanced in vitro virus neutralisation. The superior antibody response was accompanied by increased numbers of T follicular helper cells in draining lymph nodes. Vaccination with cGAMP-loaded VLPs containing haemagglutinin induced high titres of influenza A virus neutralising antibodies and conferred protection following subsequent influenza A virus challenge. Together, these results show that incorporating cGAMP into VLPs enhances their immunogenicity, making cGAMP-VLPs an attractive platform for novel vaccination strategies.Short summarycGAMP is an innate immune signalling molecule that can be transmitted between cells by inclusion in enveloped virions. This study demonstrates enhanced immunogenicity of HIV-derived virus-like particles containing cGAMP. Viral vectors loaded with cGAMP may thus be potent vaccines.


Virology ◽  
2011 ◽  
Vol 413 (2) ◽  
pp. 153-160 ◽  
Author(s):  
Fan Cheng ◽  
Suchetana Mukhopadhyay

Sign in / Sign up

Export Citation Format

Share Document